What do medical sources say about Nifedipine (Procardia, Adalat CC, Afeditab CR) during pregnancy?

1st Trimester: ACOG recommends starting or adjusting treatment for chronic high blood pressure in pregnancy at 140/90 and says people taking medicine at pregnancy start may continue unless a health reason or side effect calls for a change. MotherToBaby says first-trimester birth-defect findings are mixed: some studies found a small increase and others did not, so it is not known whether nifedipine raises the chance. Small studies of calcium-channel blockers did not find more major birth defects overall, while the Procardia XL label reports animal findings and says use in pregnancy only when potential benefits justify potential risks. Ask your provider about your situation. 2nd Trimester: ACOG recommends treatment for chronic high blood pressure in pregnancy beginning at 140/90 and says patients already taking medicine at pregnancy start may continue it absent mitigating factors or side effects. MotherToBaby reports that two calcium-channel-blocker studies, including nifedipine, found more preterm births and lower birth weights, but the authors thought the conditions being treated likely explained the findings. DailyMed reports animal reproductive findings and no adequate controlled studies in pregnant women, and limits Procardia XL use to cases where potential benefit justifies potential risk. Recent observational studies comparing nifedipine with labetalol found mixed maternal outcomes, with no clear difference in overall newborn outcomes. Ask your provider about your situation. 3rd Trimester: ACOG says immediate-release oral nifedipine may be considered first-line for acute severe high blood pressure, particularly if intravenous access is unavailable. A 2011 cohort reported more neonatal seizures after third-trimester calcium-channel-blocker exposure, but it studied the drug class, not nifedipine alone, and recorded only four seizures among 721 exposed full-term infants. A larger 2015 cohort of 22,908 calcium-channel-blocker-exposed pregnancies, including 21,449 nifedipine exposures, found no adjusted increase in neonatal seizures. MotherToBaby gives no nifedipine-specific late-pregnancy risk estimate, and the Procardia XL label notes animal findings and no adequate controlled human studies. Ask your provider about your situation.

What do medical sources say about Nifedipine (Procardia, Adalat CC, Afeditab CR) while breastfeeding?

LactMed and MotherToBaby report low amounts of nifedipine in breast milk and no reported problems in exposed infants. NHS SPS lists nifedipine as a preferred calcium-channel blocker for breastfeeding full-term, healthy infants and suggests watching for poor feeding, drowsiness, pale appearance, or slow weight gain. DailyMed takes a more cautious position than those clinical sources, limiting use to cases where potential benefit justifies potential risk. A small 2019 study measured milk levels in 19 nursing women but did not report infant blood levels or infant effects. Ask your provider about your situation.

Where do sources disagree on Nifedipine (Procardia, Adalat CC, Afeditab CR) in pregnancy or breastfeeding?

First-trimester birth-defect findings MotherToBaby says some first-trimester studies found a small increase in birth-defect risk, while other studies did not; it says whether nifedipine increases risk is not known. Prospective and population-based studies of calcium-channel blockers did not find an increase in overall major birth defects, although one study's upper digestive-tract finding was based on two exposed cases. The primary studies mostly evaluated calcium-channel blockers as a group, and some had few exposed pregnancies. MotherToBaby summarizes mixed studies without linking each finding to a specific paper. The available studies do not establish a nifedipine-specific increase in birth defects. The small exposure groups and mixed findings support describing the evidence as uncertain rather than presenting an established risk.

Back to search

Nifedipine

Medication

Procardia, Adalat CC, Afeditab CR

Calcium channel blocker

Pregnancy

MotherToBaby states that it is not known whether nifedipine increases the chance of birth defects; it reports mixed first-trimester findings. For birth defects, Magee et al. (1996) followed 78 people with first-trimester calcium-channel-blocker exposure; among 66 with outcome data, major malformations occurred in 2 exposed pregnancies versus none in controls, a difference that was not statistically significant. Davis et al. (2011) studied five US health plans; among 40 full-term infants with first-trimester calcium-channel-blocker exposure, the overall malformation risk was not increased (RR 0.96, 95% CI 0.47-1.97), while the upper digestive-tract finding involved only two exposed cases. Weber-Schoendorfer et al. (2008) compared 299 first-trimester calcium-channel-blocker exposures with 806 controls and found no increase in major birth defects; lower birth weight and more preterm births were more likely related to the underlying illness. Davis et al. also reported four neonatal seizure diagnoses among 721 full-term third-trimester calcium-channel-blocker exposures versus 196 among 75,372 unexposed infants (RR 3.61, 95% CI 1.26-10.37). The study screened many outcomes, did not adjust for multiple testing or fully control for illness, and chart review confirmed seven of ten reviewed seizure cases. Bateman et al. (2015) studied 2,529,636 term pregnancies, including 22,908 with late-pregnancy calcium-channel-blocker exposure and 21,449 nifedipine exposures; after adjustment, seizure risk was not increased (OR 0.95, 95% CI 0.70-1.30). The larger study's main analysis grouped calcium-channel blockers and cannot provide a nifedipine-specific estimate. ACOG's CHAP guidance recommends a 140/90 treatment threshold for chronic hypertension and says patients on medication at pregnancy start may continue it absent mitigating factors or side effects. ACOG Committee Opinion 767 states immediate-release oral nifedipine may be considered first-line for acute severe hypertension, particularly when IV access is unavailable. New comparative studies were mixed: Harrington et al. (2025) and Psaras et al. (2026) found similar outcomes for nifedipine and labetalol, while the Australian 2026 study associated nifedipine with higher maternal composite outcomes but no adjusted difference in composite newborn outcomes; these are observational findings and do not establish cause.

Breastfeeding

LactMed's November 2025 review reports low milk levels, small amounts ingested by infants, and no reported adverse effects. It also says published infant blood-level information was not found. NHS SPS describes nifedipine as a preferred calcium-channel blocker during breastfeeding for full-term, healthy infants, with precautionary monitoring for signs such as drowsiness, poor feeding, pale appearance, and inadequate weight gain. MotherToBaby similarly reports small amounts in milk and no reported problems, while advising families to contact the infant's clinician about excessive sleepiness or poor feeding. Malfara et al. (2019) studied 19 hypertensive breastfeeding women taking 20 mg every 12 hours; milk levels varied by ABCG2 transporter genotype, but the study did not report infant blood levels or infant effects. Small milk-level studies and clinical guidance are reassuring, but the infant-outcome evidence remains limited.

First-trimester birth-defect findings

Source A says: MotherToBaby says some first-trimester studies found a small increase in birth-defect risk, while other studies did not; it says whether nifedipine increases risk is not known. (MotherToBaby: Nifedipine fact sheet, birth-defect section)
Source B says: Prospective and population-based studies of calcium-channel blockers did not find an increase in overall major birth defects, although one study's upper digestive-tract finding was based on two exposed cases. (Magee et al., 1996, prospective cohort of calcium-channel blocker exposure, Davis et al., 2011, congenital malformations and perinatal events after calcium-channel blocker exposure, Weber-Schoendorfer et al., 2008, prospective calcium-channel blocker cohort)
Why they differ: The primary studies mostly evaluated calcium-channel blockers as a group, and some had few exposed pregnancies. MotherToBaby summarizes mixed studies without linking each finding to a specific paper.
What the evidence shows overall: The available studies do not establish a nifedipine-specific increase in birth defects. The small exposure groups and mixed findings support describing the evidence as uncertain rather than presenting an established risk.

Neonatal seizures after late-pregnancy calcium-channel-blocker exposure

Source A says: A 2011 cohort found an association between third-trimester calcium-channel-blocker exposure and neonatal seizures, based on four exposed diagnoses among 721 infants. (Davis et al., 2011, congenital malformations and perinatal events after calcium-channel blocker exposure)
Source B says: A 2015 Medicaid cohort found no adjusted increase in neonatal seizures after late-pregnancy calcium-channel-blocker exposure; 21,449 pregnancies included nifedipine exposure. (Bateman et al., 2015, late-pregnancy calcium-channel blocker exposure and neonatal seizures)
Why they differ: The 2011 study screened many outcomes and did not adjust for multiple testing or fully address differences in the illnesses being treated. The much larger 2015 cohort used propensity-score matching, but its main estimate combined several calcium-channel blockers.
What the evidence shows overall: The later, larger study did not reproduce the earlier class-level signal. It is not a nifedipine-specific proof that no risk exists, so the older finding should be disclosed with its limits.

Comparative maternal outcomes for nifedipine versus labetalol

Source A says: The Australian 2026 target-trial emulation associated nifedipine with a higher maternal composite outcome than labetalol, while finding no adjusted difference in the composite newborn outcome. (Dimitriadis et al., 2026, Australian target-trial emulation)
Source B says: A US 2025 cohort and a California 2026 cohort found similar maternal and infant outcomes for nifedipine and labetalol. (Harrington et al., 2025, US cohort comparing nifedipine and labetalol, Psaras et al., 2026, California Medicaid cohort comparing antihypertensive therapies)
Why they differ: The studies used different populations, comparison groups, and outcomes. All are observational, and residual confounding by the severity of hypertension or treatment choice remains possible.
What the evidence shows overall: The findings are mixed and do not establish that one medicine causes better outcomes. They add evidence for clinician-guided treatment but do not replace direct individualized care.

Breastfeeding label caution and clinical evidence

Source A says: DailyMed says PROCARDIA XL should be used while breastfeeding only if potential benefit justifies potential risk. (DailyMed: PROCARDIA XL nifedipine extended-release label)
Source B says: LactMed and NHS SPS report low milk transfer and no reported infant adverse effects; NHS SPS lists nifedipine as a preferred option for healthy, full-term infants. (LactMed: Nifedipine, NHS Specialist Pharmacy Service: Using calcium-channel blockers during breastfeeding)
Why they differ: The product label reflects limited controlled lactation data and uses a precautionary benefit-risk statement. LactMed and NHS SPS summarize small milk-level studies and clinical experience.
What the evidence shows overall: The clinical evidence supports a compatible rating for breastfeeding, while the product-label caution should remain visible. No established infant harm is identified in the reviewed sources.

Last reviewed 2026-10-16

Independent check 2026-10-16

Not yet clinician-reviewed

Ask your provider about your situation.

Similar medications

Amlodipine
Nitrendipine

Nifedipine

Nifedipine — Breastfeeding

What the research shows

What's in it / what was tested

Sources disagree

Options sources describe

Beyond pregnancy

All sources

Similar medications